Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Bluebird Bio
About
Bluebird Bio is a biopharma company that develops and commercializes gene therapies for the treatment of severe genetic diseases and cancer.
- Somerville,Massachusetts,United States
- 501 - 1000
- http://www.bluebirdbio.com
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- $60M
- Industries
- Biotechnology,Genetics,Health Diagnostics,Pharmaceutical
- Founded date
- Jan 1, 1993
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
- Stock Symbol
- bmv:BLUE
- Legal Name
- bluebird bio Inc.
- Also Known As
- Genetix Pharmaceuticals Inc.
bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 18, 2023 | Post-IPO Equity | $113.55M | — | — | — | Detail |
| Sep 8, 2021 | Post-IPO Equity | $75M | — | — | — | Detail |
| Jun 14, 2019 | IPO | — | — | — | — | Detail |
| Dec 7, 2016 | Post-IPO Equity | $250M | — | — | — | Detail |
| Oct 27, 2012 | Series Unknown | $9.30M | 1 |
California Institute for Regenerative Medicine
|
— | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 7, 2017
TC BioPharm
|
Series B | $16M | Biotechnology | Yes |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
California Institute for Regenerative Medicine
|
Yes | Series Unknown |
Sanofi Ventures
|
Yes | Series B |
Techno Venture Management
|
Yes | Series Unknown |
ARCH Venture Partners
|
— | Series D |
ArmaVir Partners
|
— | Series D |
Deerfield Partners
|
— | Series D |
Forbion Capital Partners
|
— | Series D |
RA Capital Management
|
— | Series D |
|
|
— | Series D |
TVM Capital
|
— | Series D |
Employee Profiles
Exits
Bluebird Bio has had 1 exits. Bluebird Bio most notable exits include TC BioPharm
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Feb 11, 2022 | TC BioPharm | IPO | Biotechnology | Detail |
